DexCom, Inc. (DXCM) Stock Analysis
Falling Knife setup · Temp Headwind edge
Healthcare · Medical Devices
Wait — supporting gate not met yet. Price is at or below entry $61.67 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source and other key suppliers.
DexCom designs and commercializes continuous glucose monitoring systems for diabetes management, with the G7 (10-day) and G7 15 Day (15.5-day) as its current products sold in the U.S. and internationally. Revenue comes from product sales through distributors, retailers, and... Read more
Wait — supporting gate not met yet. Price is at or below entry $61.67 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source and other key suppliers. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Earnings in 0 days. Wait until post-earnings. Score 6.1/10, moderate confidence.
Passes 4/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 0d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCGM systems10-K Item 1A: 'We expect that sales of our CGM systems will account for substantially all of our product revenue for the foreseeable future'
- HIGHSuppliersingle- or sole-source and other key suppliers10-K Item 1A: 'our inability to obtain sufficient quantities of supplies timely and at appropriate quality levels from our single- or sole-source and other key suppliers'
Material Events(8-K, last 90d)
- 2026-03-02Item 5.02LOWKevin R. Sayer (Executive Chairman) returned from temporary leave of absence effective March 2, 2026, per letter agreement with DexCom. Mark Foletta resumed Lead Independent Director duties upon Sayer's return. No reason cited for original leave.SEC filing →
- 2026-02-26Item 5.02LOWAlbert F. ('Rick') Osterloh IV appointed to DexCom Board of Directors effective February 26, 2026; Board size increased to 12. Appointed to Compensation and Technology Committees. No arrangement or related party interest cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait — supporting gate not met yet. Price is at or below entry $61.67 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source and other key suppliers. Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Earnings in 0 days. Wait until post-earnings. Target $78.19 (+33.8%), stop $57.28 (−2.0%), Setup A.R:R 7.3:1. Score 6.1/10, moderate confidence.
Take-profit target: $78.19 (+35.3% upside). Target $78.19 (+33.8%), stop $57.28 (−2.0%), Setup A.R:R 7.3:1. Stop-loss: $57.28.
Concentration risk — Product: CGM systems; Concentration risk — Supplier: single- or sole-source and other key suppliers.
DexCom, Inc. trades at a P/E of 27.5 (forward 19.2). TrendMatrix value score: 6.0/10. Verdict: Buy (Wait for Entry).
37 analysts cover DXCM with a consensus score of 4.2/5. Average price target: $87.
What does DexCom, Inc. do?DexCom designs and commercializes continuous glucose monitoring systems for diabetes management, with the G7 (10-day)...
DexCom designs and commercializes continuous glucose monitoring systems for diabetes management, with the G7 (10-day) and G7 15 Day (15.5-day) as its current products sold in the U.S. and internationally. Revenue comes from product sales through distributors, retailers, and pharmacy channels reimbursed by Medicare, Medicaid, and commercial insurers.